Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
CYTR [NASD]
CytRx Corporation
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.89 Insider Own15.37% Shs Outstand30.52M Perf Week2.51%
Market Cap74.77M Forward P/E- EPS next Y-0.30 Insider Trans4.45% Shs Float26.25M Perf Month-8.92%
Income-17.96M PEG- EPS next Q-0.15 Inst Own12.66% Short Float3.35% Perf Quarter13.95%
Sales0.10M P/S747.74 EPS this Y2.78% Inst Trans7.21% Short Ratio5.72 Perf Half Y45.83%
Book/sh0.99 P/B2.47 EPS next Y-2.90% ROA-46.01% Target Price8.50 Perf Year-5.41%
Cash/sh1.26 P/C1.95 EPS next 5Y- ROE-66.02% 52W Range1.59 - 5.50 Perf YTD31.02%
Dividend- P/FCF- EPS past 5Y0.00% ROI-66.02% 52W High-55.45% Beta1.25
Dividend %- Quick Ratio- Sales past 5Y-57.79% Gross Margin- 52W Low54.09% ATR0.14
Employees15 Current Ratio3.94 Sales Q/Q0.00% Oper. Margin-21052.06% RSI (14)41.12 Volatility5.11% 5.31%
OptionableYes Debt/Eq0.00 EPS Q/Q164.78% Profit Margin-17963.87% Rel Volume0.58 Prev Close2.47
ShortableYes LT Debt/Eq0.00 EarningsNov 14 Payout- Avg Volume153.68K Price2.45
Recom1.70 SMA20-6.13% SMA50-7.50% SMA200-11.86% Volume88,772 Change-0.81%
04-Dec-12Initiated Aegis Capital Buy $8
10-Sep-12Initiated Rodman & Renshaw Mkt Outperform $7
08-Jan-10Initiated Roth Capital Buy $2
03-Dec-09Initiated Merriman Buy
08-Jun-09Initiated Rodman & Renshaw Mkt Outperform $2
03-Mar-09Reiterated Brean Murray Buy $3 → $2
12-Jun-08Initiated Brean Murray Buy $3
23-Jan-08Reiterated Broadpoint Capital Buy $8 → $6.50
24-Oct-07Initiated Broadpoint Capital Buy $8
19-Oct-07Initiated Oppenheimer Buy $6
05-Apr-07Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
17-May-13 01:04PM  CYTRX CORP Financials EDGAR Online Financials
09-May-13 08:30AM  CytRx Reports 2013 First Quarter Financial Results Business Wire
01:31AM  CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
01:29AM  CYTRX CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
08-May-13 08:30AM  InPlay: CytRx provides update on clinical programs; data safety monitoring committees recommend moving forward with clinical trial with aldoxorubicin as first-line treatment for soft tissue sarcoma; discontinuing clinical trial with tamibar Briefing.com -7.84%
08:30AM  CytRx Provides Update on Clinical Programs Business Wire
07-May-13 01:58PM  Right Time To Buy This Pharmaceutical Company? at Motley Fool
06-May-13 09:34PM  3 Healthcare Stock Stories For Monday Investment Wellness at Wall St. Cheat Sheet
08:34AM  InPlay: CytRx receives recommendation from Data Safety Monitoring Committee to complete international Phase 2b trial with Aldoxorubicin as first-line treatment for soft tissue sarcoma Briefing.com
08:30AM  CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma Business Wire
29-Apr-13 12:53PM  A Tale Of Three Pharmaceuticals: Getting Exciting In 2013 at Seeking Alpha
23-Apr-13 08:31AM  InPlay: CytRx announces agreement with FDA on special protocol assessment for global pivotal phase 3 clinical trial with aldoxorubicin for soft tissue sarcoma Briefing.com
08:30AM  CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma Business Wire
19-Apr-13 02:13PM  5 Stocks Poised for Breakouts at TheStreet
22-Mar-13 09:15AM  Celsion Corp Director Buys 20K Shares and 4 Insider Trades to Note at Wall St. Cheat Sheet +6.04%
14-Mar-13 01:04PM  CYTRX CORP Financials EDGAR Online Financials -5.10%
12-Mar-13 08:32PM  New Star Analyst Rankings for CytRx Corporation StarMine -6.39%
08:30AM  CytRx to Present at the 25th Annual ROTH Conference Business Wire
11-Mar-13 09:38AM  InPlay: CytRx reports FY12 results; beats on top and bottom line; outlines goals and milestones for 2013 Briefing.com +8.13%
08:30AM  CytRx Reports 2012 Financial Results Business Wire
08:28AM  CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
01-Mar-13 08:30AM  CytRx to Present at the Cowen & Company 33rd Annual Health Care Conference Business Wire +5.24%
07:27AM  4 Stocks Under $10 Making Big Moves at TheStreet
28-Feb-13 08:30AM  CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer Business Wire +9.95%
06-Feb-13 08:30AM  CytRx to Present at the 2013 Leerink Swann Global Healthcare Conference Business Wire
04-Feb-13 08:30AM  CytRx to Present at the BIO CEO & Investor Conference Business Wire
31-Jan-13 08:31AM  InPlay: CytRx receives recommendation from Data Safety Monitoring Committee to complete global Phase 2b clinical trial with tamibarotene as first-line treatment for non-small-cell lung cancer Briefing.com
08:30AM  CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer Business Wire
29-Jan-13 09:00AM  New Drug Could Enhance the Accuracy of Chemotherapy Accesswire
09:00AM  New Drug Could Enhance the Accuracy of Chemotherapy
28-Jan-13 07:24PM  4 Healthcare Stock Stories Not to be Missed at Wall St. Cheat Sheet
08:34AM  InPlay: CytRx announces positive results from animal trial with combination aldoxorubicin and Doxorubicin Therapy Briefing.com
08:30AM  CytRx Announces Positive Results from Animal Trial with Combination Aldoxorubicin and Doxorubicin Therapy Business Wire
23-Jan-13 02:28PM  The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of CytRx Corporation in Connection with Executive Compensation PR Newswire
03-Jan-13 11:59AM  CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:30AM  CytRx Promotes Dr. Daniel Levitt to Executive Vice President Business Wire
02-Jan-13 08:30AM  CytRx to Present at the Biotech Showcase 2013 Conference Business Wire
14-Dec-12 08:21AM  Zacks #1 Rank Additions for Friday Zacks
12-Dec-12 07:53AM  Zacks #1 Rank Additions for Wednesday Zacks
11-Dec-12 01:44PM  CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04-Dec-12 01:41PM  DSW Initiated at Outperform and 3 Initiated Stocks to Track at Wall St. Cheat Sheet
12:22AM  Coverage initiated on CytRx by Aegis Capital Briefing.com
29-Nov-12 08:10AM  Zacks #1 Rank Additions for Thursday Zacks
26-Nov-12 08:25AM  FDA on Pace to Approve More New Drugs in 2012 Than the 30 Approved in 2011 Marketwire +5.98%
08:20AM  FDA on Pace to Approve More New Drugs in 2012 Than the 30 Approved in 2011 Marketwire
20-Nov-12 04:07AM  Zacks #1 Rank Additions for Tuesday Zacks
16-Nov-12 01:04PM  CYTRX CORP Financials EDGAR Online Financials
15-Nov-12 08:32AM  InPlay: CytRx announced the presentation today of favorable results from a Phase 1b/2 clinical trial; Company is planning to submit a special protocol assessment to the FDA related to its Phase 3 pivotal trial with aldoxorubicin for patient Briefing.com
08:30AM  CytRxs Aldoxorubicin Clinical Data Presented at Connective Tissue Oncology Society (CTOS) 7th Annual Meeting in Prague, Czech Republic Business Wire
12-Nov-12 09:26AM  New Star Analyst Rankings for CytRx Corporation StarMine
08:32AM  PropThink: Galena: One of Biotech's Most Vulnerable Names Thomson Reuters ONE
11-Nov-12 09:25AM  New Star Analyst Rankings for CytRx Corporation StarMine
09-Nov-12 08:34AM  CytRx says had positive meeting with FDA to discuss potential Phase 3 trial theflyonthewall.com -5.77%
08:31AM  CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
08:30AM  CytRx Reports Third Quarter 2012 Financial Results Business Wire
24-Oct-12 12:41PM  5 Stocks With Big Insider Buying at TheStreet
12:15PM  Insider filings one way to track tricky micro-cap biotechs at MarketWatch
10:38AM  The Winner Among 45 Micro-Cap Biotech Companies Competing In Self-Belief at Seeking Alpha
08:30AM  CytRx Announces Closing of Public Offering of Common Stock Business Wire
22-Oct-12 09:05AM  5 Healthcare Companies With Insider Buying During October 2012 - Part II at Seeking Alpha
08:20AM  Developers of Drugs for Deadly or Debilitating Diseases Could See Faster FDA Pathway Marketwire
19-Oct-12 12:17PM  CytRx Announces Exercise of Underwriters Over-Allotment Option Business Wire
09:50AM  Top Insider Trades: Berkshire Continues Buying DaVita at Minyanville
06:05AM  CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events EDGAR Online
18-Oct-12 10:38AM  Thursday Sector Laggards: Paper & Forest Products, Biotechnology Stocks at Forbes -19.61%
01:00AM  InPlay: CytRx prices 8 mln shares of common stock at $2.50 per share Briefing.com
17-Oct-12 09:15PM  CytRx Announces Pricing of Public Offering of 8 Million Shares of Common Stock Business Wire -11.65%
04:19PM  InPlay: CytRx announces proposed public offering of common stock... no amount given Briefing.com
04:19PM  CytRx Announces Proposed Public Offering of Common Stock Business Wire
15-Oct-12 08:31AM  InPlay: CytRx advancing aldoxorubicin (INNO-206) development with pharmacokinetic study in patients with metastatic solid tumors Briefing.com
08:30AM  CytRx Advancing Aldoxorubicin (INNO-206) Development with Pharmacokinetic Study in Patients with Metastatic Solid Tumors Business Wire
01-Oct-12 08:31AM  InPlay: CytRx aldoxorubicin clinical data presented at the ESMO 2012 Congress; The data from the aldoxorubicin Phase 1b/2 clinical trial showed clinical benefit Briefing.com
08:31AM  CytRx presents Aldoxorubicin clinical data at ESMO 2012 Congress theflyonthewall.com
08:30AM  CytRxs Aldoxorubicin Clinical Data Presented at the ESMO 2012 Congress Business Wire
20-Sep-12 08:30AM  CytRx to Present at the 2012 Aegis Healthcare Conference Business Wire
12-Sep-12 10:34AM  On The Fly: Analyst Initiation Summary theflyonthewall.com
11-Sep-12 10:21AM  On The Fly: Analyst Initiation Summary theflyonthewall.com
10-Sep-12 10:26AM  On The Fly: Analyst Initiation Summary theflyonthewall.com
10:14AM  Equity Brief: Upgrades and Downgrades for September 10th: AAPL, AEO, AIRM, AMD, AMGN, APKT, ARIA, ATR, AVAV Thomson Reuters ONE
09-Sep-12 09:23PM  Coverage initiated on CytRx by Rodman & Renshaw Briefing.com
07-Sep-12 08:30AM  CytRxs Aldoxorubicin Clinical Data Selected for Presentation at Preeminent Sarcoma Conference Business Wire
04-Sep-12 08:30AM  CytRx to Present at the Rodman & Renshaw 14th Annual Global Investment Conference Business Wire
15-Aug-12 01:04PM  CYTRX CORP Financials EDGAR Online Financials
10-Aug-12 10:26AM  New Star Analyst Rankings for CytRx Corporation StarMine
09-Aug-12 08:31AM  CYTRX CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
08:30AM  CytRx Reports Second Quarter 2012 Financial Results Business Wire
07-Aug-12 08:35AM  CytRx announces favorable results for clinical trial for aldoxorubicin theflyonthewall.com
08:30AM  CytRxs Aldoxorubicin (INNO-206) Clinical Data to Be Featured at the ESMO 2012 Congress Business Wire
25-Jul-12 12:49PM  CytRx rallies 27% on drug study update at MarketWatch +17.87%
08:32AM  CytRx initiates Phase 1b trial with combination Aldoxorubicin, Doxorubicin at theflyonthewall.com
08:30AM  CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin (INNO-206) and Doxorubicin in Patients with Advanced Solid Tumors Business Wire
17-Jul-12 08:52AM  Specialty Biotech Companies Soaring in 2012 -- Avanir Pharmaceuticals and CytRx Looking Strong Marketwire
08:30AM  CytRxs Tamibarotene Continues to Protect Touring Professional Musician and Former NBA Player Ray Johnston from Leukemia Business Wire
08:20AM  Specialty Biotech Companies Soaring in 2012 -- Avanir Pharmaceuticals and CytRx Looking Strong Marketwire
09-Jul-12 08:32AM  InPlay: CytRx announces allowance of U.S. patent application for Tamibarotene capsule Briefing.com
08:30AM  CytRx Announces Allowance of U.S. Patent Application for Tamibarotene Capsule Business Wire
05-Jul-12 05:04PM  Equity Briefing: Healthcare Review; SXCI, CYTR and MDGN Move Thomson Reuters ONE
03-Jul-12 12:03PM  5 Stocks With Big Insider Buying at TheStreet
02-Jul-12 09:14AM  3 Healthcare Companies Seeing Insider Buying In Last 3 Days - Part II at Seeking Alpha +5.90%
08:34AM  CytRx issued European patent covering INNO-206 linker technology theflyonthewall.com
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications. The aldoxorubicin is in pivotal Phase 3 preparation ongoing stage of development for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. The company also has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas; completed its Phase 1b/2 clinical trial primarily in the same indication; and initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. In addition, the company is evaluating a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patterson Scott Bradford10% OwnerApr 01Buy2.704,08311,0244,577,605Apr 03 11:00 AM
Patterson Scott Bradford10% OwnerMar 20Buy2.613,98010,3884,573,522Mar 22 05:04 PM
Patterson Scott Bradford10% OwnerMar 20Buy2.578,42021,6434,569,542Mar 20 05:06 PM
Patterson Scott Bradford10% OwnerMar 19Buy2.5824,10062,1664,561,122Mar 20 05:06 PM
Patterson Scott Bradford10% OwnerMar 18Buy2.563,0007,6674,537,022Mar 20 05:06 PM
Patterson Scott Bradford10% OwnerMar 13Buy2.523609074,534,022Mar 14 07:24 PM
Patterson Scott Bradford10% OwnerMar 11Buy2.6755,000146,7404,533,662Mar 14 07:24 PM
Patterson Scott Bradford10% OwnerOct 22Buy2.51115,000288,3284,478,662Oct 23 03:12 PM
Patterson Scott Bradford10% OwnerOct 19Buy2.5165,000163,3394,363,662Oct 23 03:12 PM
Patterson Scott Bradford10% OwnerOct 18Buy2.501,200,0003,000,0004,298,662Oct 18 02:44 PM
Patterson Scott Bradford10% OwnerJun 28Buy4.9016,00078,4323,098,662Jun 28 04:24 PM
Patterson Scott Bradford10% OwnerJun 27Buy5.2315,82482,7853,082,662Jun 28 04:24 PM
Patterson Scott Bradford10% OwnerJun 26Buy5.3213,00069,1283,066,838Jun 28 04:24 PM
Patterson Scott Bradford10% OwnerJun 25Buy5.1617,83592,0893,053,838Jun 25 05:41 PM
Patterson Scott Bradford10% OwnerJun 22Buy4.745,33425,2893,036,003Jun 25 05:41 PM
Patterson Scott Bradford10% OwnerJun 21Buy4.614,29319,7953,030,669Jun 25 05:41 PM
Patterson Scott Bradford10% OwnerJun 20Buy4.657,28333,8483,026,376Jun 20 05:01 PM
Patterson Scott Bradford10% OwnerJun 19Buy4.489,21041,2573,019,093Jun 20 05:01 PM
Patterson Scott Bradford10% OwnerJun 18Buy4.254,62119,6253,009,883Jun 20 05:01 PM
Patterson Scott Bradford10% OwnerJun 15Buy3.893,55813,8503,005,262Jun 18 04:35 PM
Patterson Scott Bradford10% OwnerJun 14Buy3.8310,97642,0633,001,704Jun 18 04:35 PM
Patterson Scott Bradford10% OwnerJun 13Buy3.8814,17655,0272,990,728Jun 14 01:02 PM
Patterson Scott Bradford10% OwnerJun 12Buy3.805,59421,2662,976,552Jun 14 01:02 PM
Patterson Scott Bradford10% OwnerJun 11Buy3.8023,39989,0142,970,958Jun 12 02:23 PM
Patterson Scott Bradford10% OwnerJun 08Buy3.8020,93379,5662,947,559Jun 12 02:23 PM
Patterson Scott Bradford10% OwnerJun 07Buy3.8553,635206,2642,926,626Jun 07 04:57 PM
Patterson Scott Bradford10% OwnerJun 06Buy3.9724,89498,7272,872,991Jun 07 04:57 PM
Patterson Scott Bradford10% OwnerJun 05Buy3.8566,704256,8972,848,097Jun 07 04:57 PM
Patterson Scott Bradford10% OwnerJun 04Buy3.53221,000779,1132,863,292Jun 04 04:51 PM
Patterson Scott Bradford10% OwnerJun 01Buy3.7486,696323,9312,642,292Jun 04 04:51 PM
Patterson Scott Bradford10% OwnerMay 31Buy3.83190,200728,9222,555,596Jun 04 04:51 PM
open in yahoo | open in reuters | open in google